SeqOne, the European leader in AI-powered software for next-generation sequencing data analysis, is proud to announce a successful funding round that raised €23,000,000. This remarkable milestone is set to accelerate the company’s mission of transforming complex genomic data into rapid, precise, and actionable insights for oncology and rare disease applications. With its state-of-the-art cloud-based platform, SeqOne has consistently empowered molecular labs to deliver life-saving diagnoses and treatments by harnessing innovative technology that streamlines the data analysis process. The recent capital infusion will be strategically deployed to enhance the platform’s capabilities, further expand its clinical applications, and broaden the company’s footprint across Europe and beyond.
The new funds will also support ongoing development efforts to reinforce the platform’s robust performance and ensure compliance, particularly as the SeqOne Platform holds CE-IVD Class C certification under IVDR as an in vitro diagnostic medical device. This certification underscores the company’s unwavering commitment to quality and regulatory adherence in a fast-evolving industry. Additionally, SeqOne is poised to deepen its research initiatives, fortify partnerships with key industry players, and invest in talent and technology to sustain its leadership position.
Having already garnered prestigious accolades such as the iLab award, the ARC Cancer Foundation’s Hélène Stark prize, and nominations for the Prix Galien award, SeqOne’s track record of excellence reflects in the trust bestowed by notable investors including Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club. As SeqOne scales the future of genomic medicine one lab at a time, this significant funding round paves the way for a new era of personalized medicine accessible to every patient, everywhere.
